Mitochondrial uncoupler BAM15 improves skeletal muscle function and mitochondrial respiration in

Sarcopenia

Dean G. Campelj[1,2], Ashleigh M. Philp[3,4], Elya J. Ritenis[1,2,5], Camila S. Padilha[1,2,6], Isabelle Alldritt[1,2], James

Sligar[2], Tabitha Cree[7,8], Stephanie J. Alexopoulos[9], Webster. L Santos[10], Sophie Joanisse[11], Paul M. Coen[12],

Kyle L. Hoehn[9], Andrew Philp[1, 6*]

[1] Centre for Healthy Ageing, Centenary Institute, Sydney, Australia

[2] Faculty of Medicine and Health, Charles Perkins Centre, University of Sydney, Sydney, Australia

[3] School of Clinical Medicine, UNSW Medicine and Health, St Vincent's Healthcare clinical campus, University

of New South Wales, Sydney, Australia

[4] Centre for Inflammation, Centenary Institute, and Faculty of Science, University of Technology Sydney,

Sydney, Australia.

[5] Department of Health Sciences and Biostatistics, Swinburne University of Technology, Melbourne, Australia.

[6] School of Sport, Exercise and Rehabilitation Sciences, University of Technology Sydney, Sydney, Australia

[7] Murdoch Children's Research Institute, The Royal Children's Hospital, Melbourne, Australia

[8] reNEW, Novo Nordisk Foundation Centre for Stem Cell Medicine, Melbourne, Australia

[9] School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, Australia.

[10] Department of Chemistry and Virginia Tech Center for Drug Discovery, Virginia Tech, Blacksburg, USA

[11] School of Life Sciences, University of Nottingham, Nottingham, United Kingdom.

[12] Translational Research Institute for Metabolism and Diabetes, AdventHealth, Orlando, USA.

*Corresponding author: andrew.philp@centenary.org.au

Abstract

Background: Ageing is accompanied by progressive declines in skeletal muscle mass and strength, culminating

in sarcopenia, a condition that contributes to frailty, multimorbidity, and mortality. Age-related changes to

mitochondria lead to oxidative damage and dysfunction and are proposed to occur early in the trajectory of

sarcopenia, supporting the candidacy of mitochondrial-protective therapies. Here, we test the efficacy of

mitochondrial uncoupler BAM15 in age-dependent sarcopenic mouse models.

Methods: Male and female MitoQC mice aged 24 months received either standard chow or chow supplemented

with BAM15 (0.033% mg/g) ad libitum for eight weeks (n=13–14/group). Young (3-month-old) mice served as

reference controls (n=8/group). Muscle mitochondrial respiration was assessed in permeabilized fibres, and

contractile function was measured in isolated extensor digitorum longus and soleus muscles. Mitophagy was

quantified by immunofluorescence confocal microscopy. Data were analyzed using one- or two-way ANOVA

followed by Dunnett's or Bonferroni's multiple comparison tests.

Results: Aged male and female mice exhibited reduced gastrocnemius muscle mass relative to body mass

compared with young controls ($p < 0.05$; ~18% and ~32% loss, respectively). BAM15 did not alter muscle size but

reversed the age-related loss of contractile function in EDL muscles, to that of the young reference controls in

both sexes ($p < 0.05$; ~33% in males, ~16% in females). In male mice, BAM15 improved mitochondrial efficiency,

evidenced by restoration of Complex I–linked respiration and decreased proton leak (~52% improvement;

$p < 0.05$), and normalized protein levels of oxidative stress marker 4-HNE, without changes in mitophagy or

mitochondrial content. In females, BAM15 did not improve mitochondrial parameters, which may be, in part, due

to aged female muscle exhibiting unchanged Complex I leak and 4-HNE protein abundance, alongside lower

complex I subunit (NDUFB8) protein abundance.

Conclusions: BAM15 improved skeletal muscle mitochondrial efficiency and contractile function in aged male

mice, supporting the potential of mitochondrial uncoupling as a therapeutic strategy for sarcopenia.

Keywords

Sarcopenia, mitochondrial uncouplers, skeletal muscle dysfunction, mitochondrial respiration, oxidative stress.

Introduction

Sarcopenia is the clinical term for age-related skeletal muscle decline, characterized by loss of muscle mass, weakness and reduced physical capacity [1]. This culminates into frailty conditions, which are associated with increased risk of falls and fractures, hospitalization, health care costs, co-morbidities and mortality [2]. To date, therapeutic interventions for the treatment of sarcopenia are limited, and those proposed often fail to show functional improvements in physical capacity [3]. Therefore, novel strategies to protect against age-related muscle decline are warranted.

Mitochondrial dysfunction is a hallmark of ageing with several mechanisms proposed [4]. Accordingly, mitochondrial uncoupler compounds are being explored as potential interventions to delay and prevent sarcopenia progression [5-7]. Mitochondria provide cellular energy for biological processes, primarily through electron transport chain (ETC) oxidative phosphorylation. This process pumps protons from the mitochondrial matrix into the intermembrane space to create the proton motive force (PMF) that couples substrate oxidation to ATP synthesis [8]. In ageing, compromised ETC functional capacity leads to elevated PMF and increased reactive oxygen species (ROS) production. Mitochondrial uncoupler compounds lower the PMF and decreases ROS production by transporting protons from the mitochondrial intermembrane space into the mitochondrial matrix [5, 6].

Here, we evaluated the mitochondrial uncoupler BAM15 as a therapeutic for sarcopenia. BAM15 is a mitochondrial-targeted protonophore ((2-fluorophenyl){6-[(2-fluorophenyl)amino](1,2,5-oxadiazolo[3,4-e]pyrazin-5-yl)}amine) that has been shown to prevent diet-induced obesity, insulin resistance [9] and skeletal muscle decline in sarcopenic-obesity mouse models [10]. Unlike traditional uncouplers such as carbonyl cyanide p-trifluoromethoxyphenylhydrazone (FCCP) [11], BAM15 does not induce mitochondrial membrane depolarization or damage and shows excellent bioavailability in skeletal muscle following oral delivery [9]. We hypothesised that short-term, mild mitochondrial uncoupling via BAM15 supplementation, would preserve skeletal muscle mitochondrial function and thereby protect against age-associated muscle decline.

Methods

Experimental protocols and treatments:

Mouse cohort

All animal experiments were conducted in compliance with Garvan Ethics Committee guidelines (21/20

protocols) and in accordance with the Australian code of practice for the care and use of animals for scientific

purposes. Mitophagy reporter mice (MitoQC) [12] were kindly provided by Professor Ian Ganley (University of

Dundee, UK). The MitoQC construct is a constitutive knockin of tandem fluorophore tag mCherry and GFP on

outer mitochondrial membrane protein FIS1 [101–153]. MitoQC colony breeding and maintenance were completed at

Australian Bioresources (Moss Vale, NSW, Australia) and genotyping was performed by Garvan Molecular

Genetics (Darlinghurst, NSW, Australia). Mice were transferred to the Biological Testing Facility at Garvan

Institute of Medical Research and were housed on a 12-hour light/dark cycle with ad libitum access to standard

rodent chow and water. Once MitoQC mice were assigned to the aging colony and became 12-months of age they

received bi-weekly health-checks and regular welfare monitoring by researchers and animal technicians until they

reached the desired experimental age, i.e., 24-months-old.

Study design

At 24 months of age, male and female MitoQC mice were randomly allocated to an 8-week diet-intervention

of standard chow (26M CHOW) or BAM15 supplemented chow (26M BAM15; (0.033% (mg/g)), with

n=14/group. The age range of 24–26 months in the C57BL/6J mouse strain corresponds with established

sarcopenia model classifications, characterized by loss of muscle mass and function [13]. These mice received

daily welfare monitoring alongside tri-weekly recording of body weight and food intake. The dosing strategy for

BAM15 was adapted from our previous work in C57BL/6J mice [9]. 1 male 26M CHOW and 1 female 26M

BAM15 supplemented mice were euthanised during treatment due to reaching ethical humane endpoints and were

excluded from analysis. Untreated 3-month-old male and female MitoQC mice (3M CON: *n*=8/group) were used

as a healthy reference control group. Power calculations were based on our previous publication [14], with a

minimum of n=8 aged mice per group was estimated to be sufficient to detect a change in muscle strength with

age. To accommodate age-related attrition, group sizes were increased by ~50%, consistent with reported survival

rates from the Jackson Laboratory of C57BL/6 mice by 28 months of age.

BAM15 Diet Preparation

BAM15 was prepared as previously described [15]. Briefly, standard chow was first powdered using a food

processor and used for all treatment groups. Powdered chow was then mixed with the correct concentration of

BAM15 and compressed into pellets using a small pellet mill (Gemco ZLSP-120B). For the standard chow diet,

powdered diet was pressed into pellets without adding any drug.

Tissue collection and processing

At study end, mice were anaesthetized using isoflurane (5% induction and 2-3% maintenance). Muscles and

organs were surgically removed, weighed and collected via snap-freezing in liquid nitrogen or immersive fixation

(3.7% PFA in 200 mM HEPES, pH 7). Exceptions include: micro-surgical harvesting of EDL and soleus (SOL)

muscles for contractility testing and collection of one gastrocnemius (GTN) muscle per mouse which was

immediately incubated in ice-cold BIOPS buffer post-harvest (2.77 mM CaK2EGTA, 7.23 mM K2EGTA, 5.77

mM Na2ATP, 6.56 mM MgCl2-6H2O, 20 mM taurine, 15 mM Na2-phosphocreatine, 20 mM imidazole, 0.5 mM

dithiothreitol, 50 mM MES hydrate, pH 7.1). Euthanasia was confirmed following cardiac removal.

Skeletal muscle contractile function

Ex vivo electrophysical testing of skeletal muscle contractility was conducted on EDL and SOL muscles as

previously described [16]. Muscles were tied at both tendons with 4.0 surgical silk thread before being excised

from the hindlimb and placed into individual organ baths of a Myodynamics Muscle Strip Myograph System

(DMT). Each organ bath was filled with a modified Krebs-Henseleit solution (NaCl 118 mM, MgSO4·7H2O 1

mM, KCl 4.75 mM, KH2PO4 1 mM, CaCl2 2.5 mM, NaHCO3 24 mM and glucose 11 mM; pH 7.4), bubbled

with carbogen (5% CO2 in O2) and maintained at 30°C. The optimal length of each muscle was established

through the delivery of sequential twitch contractions, while incrementally stretching each muscle, until the point

where the greatest twitch force produced was determined and the resting length was measured via the

micromanipulator. Next, a force–frequency protocol was performed utilizing tetanic stimulations with a square

wave of 0.2ms pulses, and a pulse train duration of 350ms and 500ms for the EDL and SOL, respectively. EDL

and SOL muscles were stimulated at an incremental range of frequencies from 10-150 Hz, with a 3-min rest in

between each stimulation. Specific force was calculated using equations as previously described [17]. To

investigate muscle resilience, muscles underwent a three-minute fatigue protocol, with EDL muscles stimulated

at 100Hz every 4s, and, SOL muscles stimulated at 80 HZ every 2s. Recovery was also assessed, with tetanic

stimulations occurring up to 15 mins post-fatigue protocol. Surgical silk was removed and muscles were blotted

before tendon-free dry mass was recorded. All data were collected and annotated using LabChart Pro version 8.0

software (ADInstruments).

High-resolution respirometry

Ex vivo mitochondrial respiration was assessed in GTN muscles by measuring oxygen consumption using an

Oxygraph-2k (OROBOROS Instruments) as previously published [18]. GTN muscles were mechanically

separated into 3-5mg fibre bundles before being permeabilized in 50 µg/µL of saponin in BIOPS buffer for 30

mins at 4 °C. Fibre bundles were weighed and loaded into Oxygraph-2k chambers calibrated and pre-loaded with

2 mL of MiRO5 buffer (0.5 mM EGTA, 3 mM $MgCl_2$-$6H_2O$, 60 mM lactobionic acid, 20 mM taurine, 10 mM

KH_2PO_4, 20 mM HEPES, 110 mM D-sucrose, 1 g/l bovine serum albumin, pH 7.1) at 37 °C. Oxygen

concentration was maintained between 150-220 µM throughout the SUIT assay. First, pyruvate (10 mM) and

malate (2 mM) were injected to stimulate respiration via ETC cycling at Complex I. ADP was then injected at

incremental concentrations of 0.1 mM, 0.175 mM, 0.25 mM, 0.5 mM, 1 mM, 2 mM, 4 mM, and 6 mM, to generate

a dose-response curve that depicts ADP-dependent oxidative phosphorylation. ADP sensitivity can then be

determined through transforming data with the Michaelis–Menten enzyme kinetics fitting model using Prism

(GraphPad Software, Inc.). Next, substrates glutamate (10 mM) and succinate (10 mM) were injected to assess

phosphorylating respiration, followed by mitochondrial uncoupler Carbonyl cyanide m-chlorophenyl hydrazone

(CCCP – 0.5 µM) to assess maximal ETC respiration. Lastly, Antimycin A (2.5 µM) was injected as a Complex

III inhibitor, which ceases mitochondrial respiration and allows for the detection of non-mitochondrial respiration.

Mitophagy assessment via immunofluorescence

Quadriceps muscles were taken out of PFA 24-48 hours post fixation and placed in cryopreservation solution

(30% sucrose in 1X PBS, pH 7) at 4 °C. Muscles were then placed in tissue moulds and embedded in optimal

cutting temperature (OCT) compound (Sakura). Longitudinal cryosections were cut at 10 µm with a NX50

Cryostar Epredia Cryostat and mounted in ProLong Diamond Antifade (Thermofisher). Images were acquired

using a Nikon C2-confocal microscope equipped with a 100X oil immersion objective. Image analysis was

performed on ImageJ using semi-automatic plugin *mito-QC Counter* [18] to quantify mitolysosomes by red

punctate counting, measuring mitolysosome size and mean channel intensities. Images were pre-processed by

applying a Gaussian blur filter with a radius of 1-1.5μm and regions of interest drawn around muscle fibres for

relative normalisation. Quantification of mitophagy was performed in 15-17 fibres per section.

Muscle lysate preparation and immunoblotting

Snap-frozen GTN muscles were prepared as previously published [18]. Briefly, GTN muscles were powdered

on dry ice using a Cellcrusher tissue pulverizer (Cellcrusher Ltd) and homogenised via shaking in a Precellys

Evolution Touch (Bertin Technologies) at 8,500 rpm for 2x 30 sec cycles in ice-cold sucrose lysis buffer (50 mM

tris pH 7.5; 270 mM sucrose; 1 mM EDTA; 1 mM EGTA; 1% triton X-100; 50 mM sodium fluoride (NaF); 1 mM

sodium orthovanadate (Na3VO4); 5 mM disodium pyrophosphate (Na2H2P2O7)) supplemented with fresh

cOmplete™ EDTA free protease inhibitor cocktail (Roche) and phosphatase inhibitor cocktail (Sigma-Aldrich).

Muscle homogenates were then centrifuged for 20 min at 14,800 rpm at 4°C to remove insoluble material and

produce muscle lysates. Protein concentrations were determined using the RC/DC protein assay as per

manufacturer's instructions (Bio-Rad). Samples were prepared by mixing equivalent protein amounts of muscle

lysates (30ug) in 4× Laemmli buffer (Bio-Rad) reduced in β-mercaptoethanol and boiled for 5 min at 95 °C. The

antibody that required an exception to this protocol was the Total OXPHOS Rodent Antibody Cocktail, where

samples remained unboiled per manufacturer's instructions. Samples were separated by SDS-PAGE on 4-15%

gradient gels (Bio-Rad) at 100 V and transferred onto nitrocellulose membranes (Bio-Rad) using a wet transfer

system at 100 V for 60 min. Membranes were then stained in Ponceau S (Sigma-Aldrich) to check for even protein

loading and transfer. Membranes were then blocked in 5% non-fat milk powder milk in tris-buffered saline with

0.1% Tween 20 (TBST) for 60 min followed by an overnight incubation at 4 °C with primary antibody dissolved

in TBST containing either 3% BSA or non-fat milk powder. Primary antibodies probed include: Total OXPHOS

Rodent Antibody Cocktail (1:1,000; ab110413; Abcam), Anti-NDUFB8 (1:1,000, ab192878, Abcam), Citrate

Synthase (1:2,500, #14309, CST) and 4 Hydroxynonenal (1:1,000, ab46545, Abcam). After overnight incubation,

membranes were washed 3 separate times for 5 min each in TBST and then probed with a horseradish peroxidase-

conjugated secondary antibody (1:10,000; anti-rabbit IgG or anti-mouse IgG; CST) in TBST for 1 hour at room

temperature. Following another set of 3 separate 10-min washes in TBST, images were developed using ECL

reagent (Millipore), captured using the ChemiDoc Touch (Bio-Rad) and quantified using ImageLab software (Bio-

Rad).

Statistics

Data are presented as Mean ± standard deviation and were analysed with GraphPad Prism v10. Normality of

the data was assessed by Shapiro-Wilk tests. For parametric data, differences between experimental groups were

determined by One-way ANOVA and Dunnet's multiple comparisons testing or Two-way ANOVA and

Bonferroni's multiple comparisons testing. To detect significant differences in non-parametric data, a Kruskal-

Wallis testing was performed followed by Dunn's multiple comparisons testing. Significance level was set at

$p<0.05$.

Results

BAM15 supplementation does not impact body and muscle mass in aged mice

To evaluate the potential therapeutic efficacy of BAM15 in sarcopenia, we supplemented 24-month-old male

and female MitoQC mice for 8 weeks with either standard chow or 0.033% admixed BAM15 (Figure 1A).

Anthropometric endpoint measures indicated that aged male and female mice had a sarcopenia-like phenotype

with increased body mass (~26% & ~39%, for males and females, respectively), and reduced quadricep mass

(~22% & ~17%, for males and females, respectively) and relative body to muscle mass ratios (~22% & ~35%,

for males and females, respectively), compared to 3-month-old healthy controls (Figure 1B-1D). BAM15

supplementation did not affect body and muscle mass in aged male or female mice (Figure 1B-1D). This was

consistent with no changes to organ mass or food intake arising from BAM15 supplementation (Supp. Figure 1).

BAM15 supplementation improves skeletal muscle contractile function in aged mice

In males, BAM15 supplementation protected against the age-associated loss of contractile function in EDL

muscles, as represented by absolute and specific force frequency relationships similar to 3M CON (Figure 2A).

BAM15 supplementation preserved EDL muscle characteristics relative to 3M CON, including; mass, optimal

length, twitch force and the rate of force development, which were all reduced in the male 26M CHOW group

(Supp. Table 1). BAM15 supplementation resulted in a greater resilience to fatigue in EDL muscles, with improved

force production during the recovery period (Figure 2A). These findings were not reflected in male SOL data,

which demonstrated lower absolute and specific force-frequency relationships, and reduced resilience to fatigue

with lower force production during the recovery period in all aged groups (Figure 2B). However, SOL twitch

characteristics demonstrated that BAM15 supplementation preserved time-to-peak, which was slower in the 26M

CHOW group, suggesting potential protection to myosin-ATPase functionality without overall improvement in

force production (Supp. Table 1). There were no additional effects on SOL twitch characteristics observed (Supp.

Table 1). Consistent with male data, BAM15 supplementation protected against the loss of contractile function in

female EDL muscles, represented by absolute and specific force frequency relationships (Figure 2C). However,

there were no changes to female EDL twitch characteristics from BAM15 supplementation (Supp. Table 2). EDL

muscles demonstrated an increase in the elasticity index, suggesting increased muscle stiffness in aged females

(Supp. Table 2). BAM15 supplementation did not affect muscle resilience to fatigue in female EDL muscles

(Figure 2C). Further, BAM15 did not affect contractility in female SOL muscles, with lower absolute and specific

force-frequency relationships, and reduced resilience to fatigue with lower force production during the recovery

period observed (Figure 2D). The rate of force development was lower in aged females (Supp. Table. 2), with no

additional significant findings found for SOL twitch characteristics.

BAM15 supplementation protects mitochondrial respiration in aged male mice

In permeabilised GTN muscle fibre bundles from males, BAM15 supplementation increased ADP-dependent

respiration, but did not alter ADP sensitivity (Figure 3A). Apparent Km data suggest that the mitochondrial

'fitness' to respond to ADP as a substrate is near completely diminished in aged muscles (~98% loss), due to

enzyme active sites reaching saturation at low ADP concentrations (Fig. 3B). BAM15 supplementation protected

against loss of Complex I leak respiration, suggestive of mild-uncoupling (Figure 3B). Further, BAM15

supplementation protected against age-related declines in Complex I and Complex I+II substrate-dependent

respiration, and maximally uncoupled respiration in sarcopenic male muscles (Figure 3B). To investigate whether

changes in mitochondrial respiration were connected to changes in mitochondrial content or oxidative stress, we

measured mitochondrial ETC complex and citrate synthase protein content via immunoblotting. There were no

changes to the protein content of mitochondrial ETC complexes I-V nor citrate synthase in aged male muscles

(Figure 3C-D). However, BAM15 supplementation protected against elevated 4-HNE content (lipid-peroxidation

marker) in aged male muscles (Figure 3C-D).

BAM15 supplementation did not protect against the reduction of ADP-dependent respiration and near-

complete ablation of ADP sensitivity (~97% loss) in aged female muscles (Figure 4A). We did not observe a loss

in Complex I leak respiration in 26M CHOW group. Subsequently, there was no change in mitochondrial

uncoupling observed through BAM15 supplementation (Figure 4B). Aged female muscles had lower Complex I

and Complex I+II substrate-dependent respiration, and maximally uncoupled respiration compared to young

reference controls, with no effect observed from BAM15 supplementation. Interestingly, we demonstrated a

reduction in Complex I subunit NDUFB8 content in aged female muscles (~30%), with some potential

remodelling of Complex IV and Complex III content from BAM15 supplementation evident (Figure 4C-D). These

findings may account, in part, for the diminished mitochondrial respiration. There were no further changes to

Complex II and V, citrate synthase or 4-HNE content in aged females (Figure 4C-D).

BAM15 supplementation does not alter skeletal muscle mitophagy in aged mice

BAM15 administration has previously been suggested to alter mitophagy-related protein content in a mouse

model of sarcopenic-obesity [10]. Thus, we employed the use of MitoQC mice to directly test whether BAM15

alters skeletal muscle mitophagy. In aged male mice, we demonstrate there are no changes to mitolysosome

abundance from BAM15 supplementation (Fig. 5A-C). When normalised to fibre area, there was no effect of age

or BAM15 supplementation observed on skeletal muscle mitophagy (Fig. 5D) However, we did observe an

increase in mitolysosome size in male 26M muscles (~52%, Fig. 5E). This may indicate alterations in mitophagic

processes or machinery which drive the accumulation of larger mitolysosomes. In aged female mice we observed

an increase in mitolysosome abundance (~76%) which is not rescued by BAM15 supplementation (Fig. 6A-C).

This is compatible with normalised data, with unsignificant trends indicating an increase in mitolysosome per

fibre area (Fig. 6D). Consistent with aged male data, female 26M mice demonstrated an increase in mitolysosome

size (~49%, Fig. 6E).

Discussion

Here we provide the first evaluation of the mitochondrial uncoupler BAM15 as a sarcopenia drug candidate in

male and female mice. We demonstrate that BAM15 supplementation does not alter age-associated loss in muscle

mass, but prevents a decline in skeletal muscle contractility and mitochondrial respiration leading to functional

improvements in sarcopenic muscle. Protection against age-related muscle functional decline was evident in both

male and female EDL muscle force production. This was consistent with previous investigation by Dantas *et al.*

where BAM15 supplementation improved 4-limb grip strength in aged high fat diet-induced obese mice [10].

Functional protection from BAM15 supplementation in aged muscle may be explained, in part, by the preservation

of muscle bioenergetics, observed as improved mitochondrial respiration and the restoration of oxidative stress

marker 4-HNE. Oxidative stress has been shown to negatively impact excitation-contraction coupling through

impaired Ca^{2+} sensitivity in aged mice and mice with global deletion of CuZn superoxide dismutase, that have

lower antioxidant activity [19]. This mechanism linking preserved muscle bioenergetics is likely to indirectly

involve protection against motor neuron degeneration, which is required for skeletal muscle dysfunction during

sarcopenia [20].

In aged male mice, BAM15 supplementation enhanced skeletal muscle resilience to fatigue. This is likely related

to improved mitochondrial function but is difficult to definitively pinpoint, given the complex nature of skeletal

muscle fatigue [21]. In aged females, BAM15 supplementation did not show changes to fatigue resilience. We

suggest this is due to female aged EDLs having a lower delta change in contractile force production due to age

when compared to males (~107mN lower in female and ~241mN lower in male aged controls compared to young

references). In EDL muscle, there seems to be a clear relationship between muscle force production and muscle

resilience to fatigue which may be a better indicator of overall muscle performance rather than fatigue

susceptibility. Age-related muscle decline has a greater burden in predominantly fast type II myo-fibre muscles

[1], which aligns with our data in the predominantly type IIB myo-fibre EDL muscle. Despite being susceptible

to age-related functional decline, SOL muscle contractility data did not follow the same protective theme arising

from BAM15 supplementation. There are examples of paradoxical mechanistic regulation between EDL and SOL

muscles, such as global myostatin knockout mice, which exhibit lower specific force production in EDL muscles,

while SOL muscles remain unaffected compared to wild-type controls [22]. A simpler explanation could be that

SOL (mixed myo-fibre type) muscle does not undergo mitochondrial decline to the same extent as the EDL,

(predominately type II myo-fibre type) during aging [23].

Previous work has demonstrated that the mitochondrial-targeted antioxidant mitoquinone mesylate (mitoQ)

did not maintain EDL muscle force production of aged mice [24], whilst the mitochondrial-targeting peptide SS-

31 (elamipretide) improved treadmill running performance and reduced fatigue susceptibility without changes to

force production in tibialis anterior muscles of aged mice [25,26]. Further, delivery of untargeted, mito-protective

compounds such as NAD^+ precursors [27, 28], oleuropein [29] and Urolithin A [30], demonstrate improved

functional capacity and/or muscle contractility in aged mice. BAM15 therefore joins a short list of mitochondrial

targeted compounds that can improve sarcopenic muscle function.

BAM15 supplementation preserved substrate-dependent phosphorylating respiration and maximally

uncoupled ETC-linked respiration without any changes in mitochondrial protein content in aged male mice. To

date, *in vivo* data has only shown that BAM15 supplemented in high-fat diet can increase mitochondrial content

and Complex II-IV activity in skeletal muscles of aged male mice [10]. In our hands, BAM15 supplementation

protected mitochondrial function, which is underscored by the attenuation of the oxidative stress marker, 4-HNE.

Tsuji *et al.* previously demonstrated that BAM15 improves survival in a mouse model of sepsis by protecting

kidneys from oxidative damage and lowering circulating mtDNA [31]. These findings are linked to the mild

uncoupling induced by BAM15, a targeted mechanism that has long been considered to reduce

oxidative/nitrosative stress and restore normative mitochondrial function [6, 32]. This will also lead to lower ROS

production rate and protection against unchecked oxidative damage from reactions instigated by single electron

reductants that can react with free oxygen and lead to superoxide (O_2^-) formation [7]. Mild uncoupling induced

by BAM15 supplementation is therefore a promising anti-oxidant strategy to protect tissues from oxidative

damage and mitochondrial respiration.

Skeletal muscle from aged female mice demonstrated a different mitochondrial phenotype compared to males.

Like male counterparts, aged female mice had lower substrate-dependent phosphorylating and maximally-

uncoupled respiration. However, this was not underlined by changes in oxidative stress or mitochondrial content

markers, rather a ~30% loss of Complex I subunit NDUFB8 protein content. To the best of our knowledge, this

finding has not previously been observed. Recently, data from Moreira-Pais *et al.* suggested that the age-dependent

remodelling of the skeletal muscle mitochondrial proteome is more pronounced in females due to reduced serum

17β-estradiol levels and the mitochondrial pool of estrogen receptor alpha (ERα) [33]. These authors also

identified downregulation of Complex 1 subunit NDUFV2 from proteomic analysis [33], suggesting some overlap

between our findings. In aged female muscles we also observe higher rates of mitophagy, with no changes in

males.

Loss of ADP sensitivity is considered to be a key representation of the metabolic decline in aged human

skeletal muscle, which is a reversible bioenergetic target of resistance training [34]. However, our data show that

aged mouse muscles show complete loss of the metabolic fitness to respond to ADP as a substrate, with near-complete saturation observed after 100 μM of ADP, regardless if supplemented with BAM15. Pharaoh *et al.* found that there is also an increase in the amount of ADP required to reduce H_2O_2 production in aged mouse muscle [35]. This was underlined by lower content of proteins involved in the transport of ADP into mitochondria, ADP/ATP translocase 2 (ANT2) and the voltage-dependent anion channel (VDAC) [35]. Additionally, there was no change in mitophagy levels from BAM15 supplementation in aged muscles. However, there was some indication of altered mitophagic processes, with larger mitolysosomes identified in both aged male and female muscles [36, 37]. Collectively, these data suggest that there is likely a nuanced redox-dependent mechanism that regulates the relative loss of metabolic fitness to respond to ADP as a substrate and ADP transporter abundance, which in turn can alter mitophagy in aged muscles.

In summary, BAM15 supplementation preserved EDL contractile function and mitochondrial respiration without altering age-related loss in muscle mass. Future investigations should explore both earlier and extended treatment durations for BAM15 supplementation, given that age-related muscle decline is typically considered to commence at ~18 months of age in mice. Our findings suggest that maintaining mitochondrial efficiency and redox balance may mitigate functional decline in sarcopenic muscle. Together, our data support mitochondrial uncoupling as a promising therapeutic strategy to preserve muscle function during the progression of sarcopenia.

Acknowledgements

This work was supported by funding from the Australian National Health and Medical Research Council awarded to A.P. (APP2013278). I.A. and A.P. were supported by Wellcome Leap's Dynamic Resilience Program (jointly funded by Temasek Trust).

This research was facilitated by access to Sydney Mass Spectrometry, a core research facility at the University of Sydney. The authors acknowledge the technical and scientific assistance of Sydney Microscopy & Microanalysis, the University of Sydney node of Microscopy Australia.

K.L.H. and W.L.S. declare commercial interest in Life Biosciences Inc and Uncoupler Biosciences.

References

1.   Larsson L, Degens H, Li M, Salviati L, Lee YI, Thompson W, et al. Sarcopenia: Aging-Related Loss of
Muscle Mass and Function. Physiol Rev. 2019;99:427-511. doi:10.1152/physrev.00061.2017

2.   Zanker J, Sim M, Anderson K, Balogun S, Brennan-Olsen SL, Dent E, et al. Consensus guidelines for
sarcopenia prevention, diagnosis and management in Australia and New Zealand. J Cachexia Sarcopenia
Muscle. 2023;14:142-56. doi:10.1002/jcsm.13115

3.   Hardee JP, Lynch GS. Current pharmacotherapies for sarcopenia. Expert Opin Pharmacother.
2019;20:1645-57. doi:10.1080/14656566.2019.1622093

4.   López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: An expanding
universe. Cell. 2023;186:243-78. doi:https://doi.org/10.1016/j.cell.2022.11.001

5.   Klaus S, Ost M. Mitochondrial uncoupling and longevity – A role for mitokines? Experimental
Gerontology. 2020;130:110796. doi:https://doi.org/10.1016/j.exger.2019.110796

6.   Brand MD. Uncoupling to survive? The role of mitochondrial inefficiency in ageing. Exp Gerontol.
2000;35:811-20. doi:10.1016/s0531-5565(00)00135-2

7.   Skulachev VP. Role of uncoupled and non-coupled oxidations in maintenance of safely low levels of
oxygen and its one-electron reductants. Quarterly Reviews of Biophysics. 1996;29:169-202.
doi:10.1017/S0033583500005795

8.   Mitchell P. Coupling of phosphorylation to electron and hydrogen transfer by a chemi-osmotic type of
mechanism. Nature. 1961;191:144-8.

9.   Alexopoulos SJ, Chen SY, Brandon AE, Salamoun JM, Byrne FL, Garcia CJ, et al. Mitochondrial
uncoupler BAM15 reverses diet-induced obesity and insulin resistance in mice. Nat Commun. 2020;11:2397.
doi:10.1038/s41467-020-16298-2

10.   Dantas WS, Zunica ERM, Heintz EC, Vandanmagsar B, Floyd ZE, Yu Y, et al. Mitochondrial
uncoupling attenuates sarcopenic obesity by enhancing skeletal muscle mitophagy and quality control. J
Cachexia Sarcopenia Muscle. 2022;13:1821-36. doi:10.1002/jcsm.12982

11.   Kenwood BM, Weaver JL, Bajwa A, Poon IK, Byrne FL, Murrow BA, et al. Identification of a novel
mitochondrial uncoupler that does not depolarize the plasma membrane. Mol Metab. 2014;3:114-23.
doi:10.1016/j.molmet.2013.11.005

12.   McWilliams TG, Prescott AR, Allen GF, Tamjar J, Munson MJ, Thomson C, et al. mito-QC illuminates
mitophagy and mitochondrial architecture in vivo. J Cell Biol. 2016;214:333-45. doi:10.1083/jcb.201603039

13.   Xie WQ, He M, Yu DJ, Wu YX, Wang XH, Lv S, et al. Mouse models of sarcopenia: classification and
evaluation. J Cachexia Sarcopenia Muscle. 2021;12:538-54. doi:10.1002/jcsm.12709

14.   Hwee DT, Baehr LM, Philp A, Baar K, Bodine SC. Maintenance of muscle mass and load-induced
growth in Muscle RING Finger 1 null mice with age. Aging Cell. 2014;13:92-101. doi:10.1111/acel.12150

15.   Chen S-Y, Beretta M, Olzomer EM, Alexopoulos SJ, Shah DP, Byrne FL, et al. Head-to-head
comparison of BAM15, semaglutide, rosiglitazone, NEN, and calorie restriction on metabolic physiology in
female db/db mice. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2024;1870:166908.
doi:https://doi.org/10.1016/j.bbadis.2023.166908

16.   Campelj DG, Timpani CA, Petersen AC, Hayes A, Goodman CA, Rybalka E. The Paradoxical Effect of
PARP Inhibitor BGP-15 on Irinotecan-Induced Cachexia and Skeletal Muscle Dysfunction. Cancers (Basel).
2020;12:doi:10.3390/cancers12123810

17.   Brooks SV, Faulkner JA. Contractile properties of skeletal muscles from young, adult and aged mice. J
Physiol. 1988;404:71-82. doi:10.1113/jphysiol.1988.sp017279

18.   Ashcroft SP, Fletcher G, Philp AM, Jenkinson C, Das S, Hansbro PM, et al. Diet-induced vitamin D
deficiency reduces skeletal muscle mitochondrial respiration. J Endocrinol. 2021;249:113-24. doi:10.1530/joe-
20-0233

19.   Qaisar R, Bhaskaran S, Premkumar P, Ranjit R, Natarajan KS, Ahn B, et al. Oxidative stress-induced
dysregulation of excitation-contraction coupling contributes to muscle weakness. J Cachexia Sarcopenia
Muscle. 2018;9:1003-17. doi:10.1002/jcsm.12339

20.   Sataranatarajan K, Qaisar R, Davis C, Sakellariou GK, Vasilaki A, Zhang Y, et al. Neuron specific
reduction in CuZnSOD is not sufficient to initiate a full sarcopenia phenotype. Redox Biol. 2015;5:140-8.
doi:10.1016/j.redox.2015.04.005

21.   Allen DG, Lamb GD, Westerblad H. Skeletal muscle fatigue: cellular mechanisms. Physiol Rev.
2008;88:287-332. doi:10.1152/physrev.00015.2007

22.   Mendias CL, Marcin JE, Calerdon DR, Faulkner JA. Contractile properties of EDL and soleus muscles
of myostatin-deficient mice. J Appl Physiol (1985). 2006;101:898-905. doi:10.1152/japplphysiol.00126.2006

23.   Crupi AN, Nunnelee JS, Taylor DJ, Thomas A, Vit JP, Riera CE, et al. Oxidative muscles have better
mitochondrial homeostasis than glycolytic muscles throughout life and maintain mitochondrial function during
aging. Aging (Albany NY). 2018;10:3327-52. doi:10.18632/aging.101643

24.	Sakellariou GK, Pearson T, Lightfoot AP, Nye GA, Wells N, Giakoumaki, II, et al. Long-term
administration of the mitochondria-targeted antioxidant mitoquinone mesylate fails to attenuate age-related
oxidative damage or rescue the loss of muscle mass and function associated with aging of skeletal muscle. Faseb
j. 2016;30:3771-85. doi:10.1096/fj.201600450R
25.	Campbell MD, Duan J, Samuelson AT, Gaffrey MJ, Merrihew GE, Egertson JD, et al. Improving
mitochondrial function with SS-31 reverses age-related redox stress and improves exercise tolerance in aged
mice. Free Radic Biol Med. 2019;134:268-81. doi:10.1016/j.freeradbiomed.2018.12.031
26.	Siegel MP, Kruse SE, Percival JM, Goh J, White CC, Hopkins HC, et al. Mitochondrial-targeted
peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice. Aging Cell.
2013;12:763-71. doi:10.1111/acel.12102
27.	Membrez M, Migliavacca E, Christen S, Yaku K, Trieu J, Lee AK, et al. Trigonelline is an NAD(+)
precursor that improves muscle function during ageing and is reduced in human sarcopenia. Nat Metab.
2024;6:433-47. doi:10.1038/s42255-024-00997-x
28.	Dimet-Wiley AL, Latham CM, Brightwell CR, Neelakantan H, Keeble AR, Thomas NT, et al.
Nicotinamide N-methyltransferase inhibition mimics and boosts exercise-mediated improvements in muscle
function in aged mice. Sci Rep. 2024;14:15554. doi:10.1038/s41598-024-66034-9
29.	Gherardi G, Weiser A, Bermont F, Migliavacca E, Brinon B, Jacot GE, et al. Mitochondrial calcium
uptake declines during aging and is directly activated by oleuropein to boost energy metabolism and skeletal
muscle performance. Cell Metabolism. 2024;doi:https://doi.org/10.1016/j.cmet.2024.10.021
30.	Ryu D, Mouchiroud L, Andreux PA, Katsyuba E, Moullan N, Nicolet-Dit-Félix AA, et al. Urolithin A
induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents. Nat Med.
2016;22:879-88. doi:10.1038/nm.4132
31.	Tsuji N, Tsuji T, Yamashita T, Hayase N, Hu X, Yuen PS, et al. BAM15 treats mouse sepsis and kidney
injury, linking mortality, mitochondrial DNA, tubule damage, and neutrophils. J Clin Invest.
2023;133:doi:10.1172/jci152401
32.	Murphy MP. How mitochondria produce reactive oxygen species. Biochem J. 2009;417:1-13.
doi:10.1042/bj20081386
33.	Moreira-Pais A, Vitorino R, Sousa-Mendes C, Neuparth MJ, Nuccio A, Luparello C, et al.
Mitochondrial remodeling underlying age-induced skeletal muscle wasting: let's talk about sex. Free Radical
Biology and Medicine. 2024;218:68-81. doi:https://doi.org/10.1016/j.freeradbiomed.2024.04.005
34.	Holloway GP, Holwerda AM, Miotto PM, Dirks ML, Verdijk LB, van Loon LJC. Age-Associated
Impairments in Mitochondrial ADP Sensitivity Contribute to Redox Stress in Senescent Human Skeletal
Muscle. Cell Reports. 2018;22:2837-48. doi:https://doi.org/10.1016/j.celrep.2018.02.069
35.	Pharaoh G, Brown J, Ranjit R, Ungvari Z, Van Remmen H. Reduced adenosine diphosphate sensitivity
in skeletal muscle mitochondria increases reactive oxygen species production in mouse models of aging and
oxidative stress but not denervation. JCSM Rapid Commun. 2021;4:75-89. doi:10.1002/rco2.29
36.	Hoshino A, Wang WJ, Wada S, McDermott-Roe C, Evans CS, Gosis B, et al. The ADP/ATP translocase
drives mitophagy independent of nucleotide exchange. Nature. 2019;575:375-9. doi:10.1038/s41586-019-1667-
4
37.	Ham SJ, Lee D, Yoo H, Jun K, Shin H, Chung J. Decision between mitophagy and apoptosis by Parkin
via VDAC1 ubiquitination. Proc Natl Acad Sci U S A. 2020;117:4281-91. doi:10.1073/pnas.1909814117

   Figures:

471   **Figure 1: Body mass and muscle mass are unchanged from BAM15 supplementation in aged sarcopenic**

472   **mice.** A) Infographic of the mouse model and experimental design. B) Endpoint body mass, C) skeletal muscle

473   mass (TA: tibialis anterior; TRI: triceps; GSN: gastrocnemius; QD: quadriceps) and D) skeletal muscle to body

474   mass ratios shown. Data is presented as mean ± SD. n=7-8 per group for 3M CON; n=13-14 per group for 26M

475   males and females. *p,0.05; **$p<0.01$; ***$p<0.001$ vs 3M CON.

Figure 2: BAM15 supplementation improves EDL muscle contractile function in sarcopenic male and female mice. Ex vivo contractile function assessment was performed in extensor digitorum longus (EDL) and soleus (SOL) muscles. Male A) EDL and B) SOL muscles are analysed with force-frequency relationships showing absolute and specific force (normalised to physiological cross-sectional area) production across a range of frequencies in the EDL. Muscle resilience was tested with absolute force produced during the fatigue stimulus

484 and recovery period shown. This contractile testing battery was repeated in female C) EDL and D) SOL muscles.

485 Data is presented as mean ± SD. n=8 for 3M CON males and n=5-6 per group for 26M old males. n=8-9 per group

486 for females. *$p<0.05$; **$p<0.01$; ***$p<0.001$ 26M CON vs 3M CON. ^ $p<0.05$ 26M BAM15 vs 3M CON.

Figure 3: BAM15 supplementation preserves skeletal muscle mitochondrial respiration but does not impact content abundance in sarcopenic male mice. Using permeabilized fibre bundles from male gastrocnemius muscles mitochondrial respiration was assessed via high resolution respirometry. A) Respiration is stimulated via an ADP titration in the presence of pyruvate and malate with standard and transformed data (via the Michaelis–Menten kinetics equation) presented. B) Apparent Km which represents the required concentration of ADP required to reach 50% of the maximal ADP-dependent respiration, Complex 1 Leak respiration, phosphorylating respiration (CI_P) in the presence of Complex I substrate (glutamate) and Complex I+II substrates (glutamate and succinate – $CI+II_P$) and CCCP-induced maximal uncoupled respiration are shown. Protein abundance was

measured via immunoblotting with OXPHOS subunits Complex V (ATP5A), Complex IV (MTCO1), Complex

III (UQCRC2), Complex II (SDHB) and Complex I (NDUFB8), alongside Citrate Synthase and 4-

Hydroxynonenal (4-HNE) probed. C) Representative images for antibodies and Ponceau for protein loading are

shown and D) data quantified relative to 3M CON. Data is presented as mean ± SD. n=7-12 per group for

mitochondrial respiration analyses; n= 7-8 per group for immunoblotting analyses. *p,0.05; **$p<0.01$;

***$p<0.001$; ****$p<0.0001$ 26M CON vs 3M CON. ^ $p<0.05$ 26M BAM15 vs 3M CON.

Figure 4: BAM15 supplementation does not alter skeletal muscle mitochondrial respiration or content abundance in sarcopenic female mice. Using permeabilized fibre bundles from male gastrocnemius muscles mitochondrial respiration was assessed via high resolution respirometry. A) Respiration is stimulated via an ADP titration in the presence of pyruvate and malate with standard and transformed data (via the Michaelis–Menten kinetics equation) presented. B) Apparent Km which represents the required concentration of ADP required to reach 50% of the maximal ADP-dependent respiration, Complex 1 Leak respiration, phosphorylating respiration

(CI_p) in the presence of Complex I substrate (glutamate) and Complex I+II substrates (glutamate and succinate –

$CI+II_p$) and CCCP-induced maximal uncoupled respiration are shown. Protein abundance was measured via

immunoblotting with OXPHOS subunits Complex V (ATP5A), Complex IV (MTCO1), Complex III (UQCRC2),

Complex II (SDHB) and Complex I (NDUFB8), alongside Citrate Synthase and 4-Hydroxynonenal (4-HNE)

probed. C) Representative images for antibodies and Ponceau for protein loading are shown and D) data quantified

relative to 3M CON. Data is presented as mean ± SD. n=9-10 per group for mitochondrial respiration analyses;

n= 7-8 per group for immunoblotting analyses. *p,0.05; **$p<0.01$; ***$p<0.001$; ****$p<0.0001$ 26M CON vs 3M

CON. ^ $p<0.05$ 26M BAM15 vs 3M CON.

Figure 5: BAM15 supplementation does not alter skeletal muscle mitophagy status in sarcopenic male mice.
Fixed quadriceps muscles were embedded in OCT and longitudinally sectioned for mitophagy quantitation via measurement of MitoQC reporter fluorophores GFP and mCherry using confocal microscopy. A) Representative images are displayed, alongside B) mean intensity ratio of the red and green channels, C) total number of mitolysosomes, D) mitolysosomes per fibre area and E) mitolysosome size reported. Data is presented as mean ± SD. 15-17 fibres analysed per section. n=6 for 3M CON; n= 10-14 per group for 26M males. *p,0.05; **$p<0.01$; ***$p<0.001$; 26M CON vs 3M CON.

Figure 6: BAM15 supplementation does not alter skeletal muscle mitophagy status in sarcopenic female mice. Fixed quadriceps muscles were embedded in OCT and longitudinally sectioned for mitophagy quantitation via measurement of MitoQC reporter fluorophores GFP and mCherry using confocal microscopy. A) Representative images are displayed, alongside B) mean intensity ratio of the red and green channels, C) total number of mitolysosomes, D) mitolysosomes per fibre area and E) mitolysosome size reported. Data is presented as mean ± SD. 15-17 fibres analysed per section. n=7 for 3M CON; n= 10-12 per group for 26M females. *p,0.05; **p<0.01; ***p<0.001; 26M CON vs 3M CON.

588